Products & pipeline
Mirnow Prostate
A blood- and urine-based microRNA test designed to help urologists assess prostate cancer risk in men with raised PSA, and so support the decision on whether a biopsy is needed.
Investigational test. Not yet available for clinical use. Performance is being established in ongoing studies.
- Intended population (under study)
- Men aged 45 and over, PSA >4 ng/mL, considering a first or repeat biopsy
- Sample
- A routine blood draw and urine sample collection
- Technology
- RT-qPCR panel interpreted by a proprietary ML model
- Status
- In prospective multicentre clinical validation
Pipeline
One platform, more indications.
Each new test reuses the same backbone (sample handling, RT-qPCR measurement and machine learning) so we can add indications faster. Over time, we aim to offer validated tests both as a central laboratory service and as kits for diagnostic labs.
| Programme | Sample | Discovery | Early research | Pilot studies | Clinical validation |
|---|---|---|---|---|---|
| Prostate cancer risk test | Blood | ||||
| Prostate cancer two-tier test | Urine (exosomal RNA) | ||||
| Bladder cancerPublished proof of concept | Urine (exosomal miRNA) | ||||
| Further cancers | Blood / urine | ||||
Platform development: Multi-omics diagnostics · AI clinical decision support · Federated learning platform
Help us validate the test.
Urologists and clinical sites can join our ethics-approved study.